MX381271B - Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana - Google Patents
Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacterianaInfo
- Publication number
- MX381271B MX381271B MX2014000066A MX2014000066A MX381271B MX 381271 B MX381271 B MX 381271B MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 381271 B MX381271 B MX 381271B
- Authority
- MX
- Mexico
- Prior art keywords
- gel formulations
- bacterial vaginosis
- treat bacterial
- metronidazole
- mucoadhesive gel
- Prior art date
Links
- 208000004926 Bacterial Vaginosis Diseases 0.000 title abstract 2
- 208000037009 Vaginitis bacterial Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000282 metronidazole Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502285P | 2011-06-28 | 2011-06-28 | |
| US201161508058P | 2011-07-14 | 2011-07-14 | |
| PCT/US2012/044738 WO2013003646A1 (en) | 2011-06-28 | 2012-06-28 | High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000066A MX2014000066A (es) | 2014-05-01 |
| MX381271B true MX381271B (es) | 2025-03-11 |
Family
ID=47391265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000066A MX381271B (es) | 2011-06-28 | 2012-06-28 | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8946276B2 (https=) |
| EP (1) | EP2725904B1 (https=) |
| JP (2) | JP5986632B2 (https=) |
| CN (2) | CN107823123A (https=) |
| AU (2) | AU2012275292B2 (https=) |
| BR (1) | BR112013033759B1 (https=) |
| CA (2) | CA2840571C (https=) |
| MX (1) | MX381271B (https=) |
| WO (1) | WO2013003646A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201590008A1 (ru) | 2012-06-13 | 2015-05-29 | Ивофем, Инк. | Композиции и способы повышения эффективности бактерицидных средств контрацепции |
| US9446024B2 (en) | 2013-06-25 | 2016-09-20 | UNIVERSITé LAVAL | Formulations for the treatment of vaginal disorders |
| JP2017501227A (ja) | 2013-12-19 | 2017-01-12 | エヴォフェム，インク． | アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 |
| KR20170052626A (ko) * | 2014-09-05 | 2017-05-12 | 심바이오믹스 세러퓨틱스 엘엘씨 | 세균질증 치료에 사용하기 위한 세크니다졸 |
| CA2988082C (en) | 2015-06-01 | 2020-09-29 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| US10759740B2 (en) | 2016-03-24 | 2020-09-01 | Rutgers, The State University Of New Jersey | Antibacterial agents |
| US11419835B2 (en) | 2016-10-04 | 2022-08-23 | Evofem, Inc. | Method of treatment and prevention of bacterial vaginosis |
| SE1750680A1 (en) * | 2017-05-30 | 2018-12-01 | Peptonic Medical Ab | Composition for treating or preventing climacteric disorders |
| US20200126094A1 (en) * | 2018-10-19 | 2020-04-23 | BioIDC, Inc. | Medical research fraud detection system and software |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837378A (en) | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
| WO1988006888A1 (en) | 1987-03-20 | 1988-09-22 | Curatek Pharmaceuticals, Inc. | Novel topical metronidazole formulations and therapeutic uses thereof |
| US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| CA1337279C (en) | 1989-06-06 | 1995-10-10 | Robert J. Borgman | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| EP0537784B1 (en) | 1991-10-18 | 1995-03-01 | Dow Corning Corporation | Silicone pressure sensitive adhesives having enhanced adhesion to low energy substrates |
| IT1284874B1 (it) * | 1996-08-02 | 1998-05-22 | Farmigea Spa | Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici |
| GB9626513D0 (en) | 1996-12-20 | 1997-02-05 | Bioglan Ireland R & D Ltd | A pharmaceutical composition |
| DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
| WO1998014768A2 (en) | 1997-10-06 | 1998-04-09 | Schwartz Sorell L | Transdermal chemical monitoring device |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6881726B2 (en) | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
| US7368122B1 (en) | 2002-03-08 | 2008-05-06 | Dow Pharmaceutical Sciences | Skin cream |
| US20050186142A1 (en) | 2002-10-25 | 2005-08-25 | Foamix Ltd. | Kit and composition of imidazole with enhanced bioavailability |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US7456207B2 (en) * | 2003-09-25 | 2008-11-25 | Teva Pharmaceuticals Usa, Inc. | Vaginal pharmaceutical compositions and methods for preparing them |
| FR2887149B1 (fr) | 2005-06-17 | 2007-08-03 | Galderma Sa | Procede de solubilisation du metronidazole |
| US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| FR2882552B1 (fr) | 2005-02-25 | 2008-12-26 | Galderma Sa | Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation |
| AU2006298442A1 (en) | 2005-05-09 | 2007-04-12 | Foamix Ltd. | Saccharide foamable compositions |
| CA2611577A1 (en) | 2005-06-07 | 2007-09-07 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
| FR2890559B1 (fr) | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour la preparation |
| FR2890560B1 (fr) | 2005-09-13 | 2011-06-24 | Galderma Sa | Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation |
| BRPI0617693A2 (pt) | 2005-11-09 | 2011-08-02 | Dow Pharmaceutical Sciences | azitromicina para o tratamento de rosácea granulomatosa |
| CN101374501A (zh) | 2006-01-05 | 2009-02-25 | 药物技术公司 | 组合物及其使用方法 |
| FR2899475A1 (fr) | 2006-04-10 | 2007-10-12 | Galderma Res & Dev | Composition pharmaceutique pour le traitement de la rosacee |
| EP2029106A2 (en) | 2006-06-07 | 2009-03-04 | Foamix Ltd. | Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof |
| US20080287515A1 (en) * | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080287514A1 (en) | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080287513A1 (en) | 2007-05-14 | 2008-11-20 | Jerry Zhang | Topical compositions containing metronidazole |
| US20080312304A1 (en) | 2007-06-13 | 2008-12-18 | Jerry Zhang | Topical compositions containing metronidazole |
| US7893097B2 (en) * | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
| US20100105750A1 (en) | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
| CA2790682C (en) | 2010-03-03 | 2020-11-24 | Neocutis Sa | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
-
2012
- 2012-06-28 JP JP2014519052A patent/JP5986632B2/ja active Active
- 2012-06-28 US US13/536,960 patent/US8946276B2/en active Active
- 2012-06-28 AU AU2012275292A patent/AU2012275292B2/en active Active
- 2012-06-28 WO PCT/US2012/044738 patent/WO2013003646A1/en not_active Ceased
- 2012-06-28 CA CA2840571A patent/CA2840571C/en active Active
- 2012-06-28 EP EP12804805.5A patent/EP2725904B1/en active Active
- 2012-06-28 MX MX2014000066A patent/MX381271B/es unknown
- 2012-06-28 CN CN201710998632.5A patent/CN107823123A/zh active Pending
- 2012-06-28 CN CN201280040540.1A patent/CN103763925A/zh active Pending
- 2012-06-28 BR BR112013033759-1A patent/BR112013033759B1/pt active IP Right Grant
- 2012-06-28 CA CA3054236A patent/CA3054236A1/en not_active Abandoned
- 2012-08-23 US US13/593,386 patent/US9198858B2/en active Active
-
2015
- 2015-10-23 US US14/921,737 patent/US10238634B2/en active Active
-
2016
- 2016-02-09 AU AU2016200825A patent/AU2016200825B2/en active Active
- 2016-08-05 JP JP2016154447A patent/JP6235087B2/ja active Active
-
2019
- 2019-01-14 US US16/247,497 patent/US10596155B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103763925A (zh) | 2014-04-30 |
| US10596155B2 (en) | 2020-03-24 |
| US10238634B2 (en) | 2019-03-26 |
| CN107823123A (zh) | 2018-03-23 |
| EP2725904A1 (en) | 2014-05-07 |
| AU2016200825B2 (en) | 2017-10-26 |
| US20130005787A1 (en) | 2013-01-03 |
| BR112013033759A8 (pt) | 2018-07-31 |
| WO2013003646A1 (en) | 2013-01-03 |
| CA3054236A1 (en) | 2013-01-03 |
| CA2840571C (en) | 2020-03-24 |
| JP2014518272A (ja) | 2014-07-28 |
| US8946276B2 (en) | 2015-02-03 |
| EP2725904A4 (en) | 2014-12-10 |
| CA2840571A1 (en) | 2013-01-03 |
| MX2014000066A (es) | 2014-05-01 |
| BR112013033759A2 (pt) | 2016-08-16 |
| AU2012275292A1 (en) | 2014-01-23 |
| EP2725904B1 (en) | 2024-12-11 |
| JP2017014248A (ja) | 2017-01-19 |
| US9198858B2 (en) | 2015-12-01 |
| BR112013033759B1 (pt) | 2021-05-25 |
| US20130005785A1 (en) | 2013-01-03 |
| AU2012275292B2 (en) | 2015-11-12 |
| AU2016200825A1 (en) | 2016-03-03 |
| JP5986632B2 (ja) | 2016-09-06 |
| US20190183859A1 (en) | 2019-06-20 |
| JP6235087B2 (ja) | 2017-11-22 |
| US20160106714A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381271B (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| CO6351786A2 (es) | Inkibidores de la cinasa map p38 | |
| UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
| EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MX2008016453A (es) | Composiciones y metodos para tratar infecciones parasitas. | |
| UA110103C2 (uk) | Модифікований туберкульозний антиген | |
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| EA201370018A1 (ru) | Составы рифаксимина и их применение | |
| UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
| UY33276A (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso | |
| MX377170B (es) | Composiciones de gel de brimonidina y metodos de uso. | |
| CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| UA109557C2 (uk) | Похідні 2-піперазин-1-іл-4h-1,3-бензотіазин-4-ону та їх застосування для лікування інфекцій у ссавців | |
| MX2014006686A (es) | Derivaods novedosos de pirrol. | |
| BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual |